Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.
NCT ID: NCT01375400
Last Updated: 2011-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences.
Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke
NCT01273935
Study of Aspirin and TPA in Acute Ischemic Stroke
NCT00417898
Role of Anti-platelet in Treatment of Acute Ischemic Stroke
NCT03266731
Low-dose Aspirin Therapy in Patients With Ischemic Stroke and Microbleeds
NCT04504864
Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke
NCT01790997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin
Administration of 300 mg of aspirin, per os.
blood sample
2 blood samples will be performed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ischemic stroke less than 48 hours
* Signed consent
Exclusion Criteria
* Prescription of heparin or VKA
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CentralHNF
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital central
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Aspirin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.